Innovation
Dr. Huber joined Third Rock Ventures in 2018 as Partner. Third Rock is one of the industries preeminent life sciences company creation firms based in Boston, MA. At Third Rock, Dr. Huber is focused on discovering, launching and building highly innovative, value-creating, product engine-focused companies across multiple therapeutic areas. Prior to Third Rock, Dr. Huber was at Incyte Corporation which he joined in 2002 as a member of the founding scientific team, and most recently served as the company’s Executive Vice President and Chief Scientific Officer. Under Dr. Huber’s leadership, Incyte’s research labs have brought forward >25 therapeutics into clinical development over 16 years, including the janus kinase (JAK) inhibitors ruxolitinib (Jakafi®; approved for the treatment of myelofibrosis and polycythemia vera) and baricitinib (Olumiant®; approved for the treatment of rheumatoid arthritis), as well as therapeutics in late-stage/Phase 3 development for genetic sub-types of cholangiocarcinoma and bladder cancer (pemigatinib) and lung cancer (capmatinib); as well as lymphoma (parsaclisib) and graft vs host disease (itacitinib). Before joining Incyte, Dr. Huber held scientific research positions at DuPont Pharmaceuticals and Bristol-Myers Squibb from 1997 to 2002. Dr. Huber received his PhD in molecular genetics from the Washington University School of Medicine and held pre- and post-doctoral fellowships at the National Institutes of Health. Dr. Huber serves on the Board of Directors of Bellicum, a company focused on developing novel cellular therapies for cancer and orphan inherited blood disorders; as well as the B+ Foundation, the nation’s largest provider of financial assistance to families of children with cancer.
Back to Innovation Growth Board